Home » Topics » Regulatory » EMA

EMA
RSS

EMA recommends granting orphan status to Aspireo's somatoprim

Nov. 26, 2012

EMA to begin formal review of macitentan MAA

Nov. 22, 2012

Zytiga receives positive CHMP recommendation for castration-resistant prostate cancer

Nov. 20, 2012

CHMP recommends Exjade approval for non-transfusion-dependent thalassemia syndromes

Nov. 20, 2012

EMA committee recommends approval of lixisenatide

Nov. 19, 2012

CHMP recommends approval of Novartis's meningococcal group B vaccine

Nov. 19, 2012

Zaltrap receives positive CHMP opinion for metastatic colorectal cancer

Nov. 19, 2012

European Commission denies marketing authorization for taliglucerase alfa

Nov. 5, 2012

EMA accepts for review lurasidone MAA

Oct. 25, 2012

Xalkori granted conditional approval in Europe

Oct. 25, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...